CoChat
Sign Up
Cited by 602Substance Abuse Treatment and OutcomesGambling Behavior and TreatmentsOpioid Use Disorder Treatment

Substance Abuse in Women

Open access
Greenfield, Shelly F., Back, Sudie E., Lawson, Katie, Brady, Kathleen T.·2010·Psychiatric Clinics of North America
DOI 10.1016/j.psc.2010.01.004PMC PMC3124962
Open this paper in CoChat — free account

Abstract

Gender differences in substance use disorders (SUDs) and treatment outcomes for women with SUDs have been a focus of research in the last 15 years. This article reviews gender differences in the epidemiology of SUDs, highlighting the convergence of male/female prevalence ratios of SUDs in the last 20 years. The telescoping course of SUDs, recent research on the role of neuroactive gonadal steroid hormones in craving and relapse, and sex differences in stress reactivity and relapse to substance abuse are described. The role of co-occurring mood and anxiety, eating, and posttraumatic stress disorders is considered in the epidemiology, natural history, and treatment of women with SUDs. Women's use of alcohol, stimulants, opioids, cannabis, and nicotine are examined in terms of recent epidemiology, biologic and psychosocial effects, and treatment. Although women may be less likely to enter substance abuse treatment than men over the course of the lifetime, once they enter treatment, gender itself is not a predictor of treatment retention, completion, or outcome. Research on gender-specific treatments for women with SUDs and behavioral couples treatment has yielded promising results for substance abuse treatment outcomes in women.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.psc.2010.01.004

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • There is no evidence of sex differences in treatment outcomes.

    “By contrast, there is no evidence of sex differences in treatment outcomes 337 .”

    From Substance use disorders: a comprehensive update of classification, epidemiology, neurobiology, clinical aspects, treatment and prevention (2023) · cites this paper as [337]

    The “Treatment Outcome for Women with Substance-use Disorders” section says that, once women enter treatment, gender itself does not predict retention, completion, or outcome. The claim omits that condition and states the point more broadly than the paper does; the same section notes that some factors and treatment approaches can affect outcomes differently by gender. Page numbers were not provided in our copy. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 101

  1. [1]Compton WM Thomas YF Stinson FS Prevalence, correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions Arch Gen Psychiatry 2007 64 566 76 17485608
  2. [3]Grucza RA Norberg K Bucholz KK Correspondence between secular changes in alcohol dependence and age of drinking onset among women in the United States Alcohol Clin Exp Res 2008 32 8 1493 501 18564104 PMC2661151
  3. [4]Wagner FA Anthony JC Male-female differences in the risk of progression from first use to dependence upon cannabis, cocaine, and alcohol Drug Alcohol Depend 2007 86 191 8 17029825
  4. [5]Helzer JE Burnam A McEvoy LT Robins LN Regier DA Alcohol abuse and dependence Psychiatric disorders in America: the epidemiological catchment area study 1991 81 115 The Free Press New York
  5. [7]Simoni-Wastila L Ritter G Strickler G Gender and other factors associated with the nonmedical use of abusable prescription drugs Subst Use Misuse 2004 39 1 1 23 15002942
  6. [8]Blanco C Alderson D Ogburn E Changes in the prevalence of non-medical prescription drug use and drug use disorders in the United States: 1991–1992 and 2001–2002 Drug Alcohol Depend 2007 90 2–3 252 60 17513069
  7. [9]Hernandez-Avila CA Rounsaville BJ Kranzler HR Opioid-, cannabis-, and alcohol-dependent women show more rapid progression to substance abuse treatment Drug Alcohol Depend 2004 74 3 265 72 15194204
  8. [10]Hser YI Anglin MD Booth MW Sex differences in addict careers: 3. Addiction Am J Drug Alcohol Abuse 1987 13 3 231 51 3687889
  9. [11]Randall CL Roberts JS Del Boca FK Telescoping of landmark events associated with drinking: a gender comparison J Stud Alcohol 1999 60 252 60 10091964
  10. [12]Newman JL Mello NK Brady KT Back SE Greenfield SF Neuroactive gonadal steroid hormones and drug addiction in women Women and addiction: a comprehensive handbook 2009 35 64 Guilford Press New York
  11. [13]Doron R Fridman L Gispan-Herman I DHEA, a neurosteroid, decreases cocaine self-administration and reinstatement of cocaine-seeking behavior in rats Neuropsychopharmacology 2006 31 10 2231 6 16421515
  12. [14]Sofuoglu M Dudish-Poulsen S Nelson D Sex and menstrual cycle differences in the subjective effects from smoked cocaine in humans Exp Clin Psychopharmacol 1999 7 3 274 83 10472516
  13. [15]Evans SM Foltin RW Exogenous progesterone attenuates the subjective effects of smoked cocaine in women, but not in men Neuropsychopharmacology 2006 31 3 659 74 16160708
  14. [16]Perkins KA Levine M Marcus M Tobacco withdrawal in women and menstrual cycle phase J Consult Clin Psychol 2000 68 1 176 80 10710853
  15. [17]Holdstock L de Wit H Effects of ethanol at four phases of the menstrual cycle Psychopharmacology 2000 150 374 82 10958078
  16. [19]Sinha R Fox H Hong KI Sex steroid hormones, stress response, and drug craving in cocaine-dependent women: implications for relapse susceptibility Exp Clin Psychopharmacol 2007 15 5 445 52 17924778
  17. [20]Back SE Waldrop AE Saladin ME Effects of gender and cigarette smoking on reactivity to psychological and pharmacological stress provocation Psychoneuroendocrinology 2008 33 5 560 8 18321653 PMC2446474
  18. [21]Fox HC Hong KA Paliwal P Altered levels of sex and stress steroid hormones assessed daily over a 28-day cycle in early abstinent cocaine-dependent females Psychopharmacology 2008 195 4 527 36 17891383 PMC2746368
  19. [23]Goldstein RB Brady KT Back SE Greenfield SF Comorbidity of substance use with independent mood and anxiety disorders in women: results from the National Epidemiologic Survey on Alcohol and Related Conditions Women and addiction: a comprehensive handbook 2009 173 92 Guilford Press New York
  20. [24]Greenfield SF Westermeyer J Weiss RD Ziedonis D Assessment of mood and substance use disorders Integrated treatment for mood and substance use disorders 2003 432 67 Johns Hopkins University Press Baltimore (MD)
  21. [25]Pettinati HM Dundon W Lipkin C Gender differences in response to sertraline pharmacotherapy in type A alcohol dependence Am J Addict 2004 13 3 236 47 15370943
  22. [27]Holderness CC Brooks-Gunn J Warren MP Co-morbidity of eating disorders and substance abuse: review of the literature Int J Eat Disord 1994 16 1 34 7920577
  23. [28]Dohm FA Striegal-Moore R Wilfley DE Self harm and substance use in a community sample of black and white women with binge eating disorders or bulimia nervosa Intl J Eat Disord 2002 32 389 400 12386904
  24. [30]Gordon SM Johnson JA Greenfield SF Assessment and treatment of co-occurring eating disorders in publicly funded addiction treatment programs Psychiatr Serv 2008 59 1056 9 18757602 PMC3417144
  25. [31]Cottler LB Compton WM Mager D Post-traumatic stress disorder among substance users from the general population Am J Psychiatry 1992 149 664 70 1575258
  26. [32]Mills KL Teesson M Ross J Trauma, PTSD, and substance use disorders: findings from the Australian National Survey on mental health and well-being Am J Psychiatry 2006 163 652 8 16585440
  27. [33]Najavits LM Weiss R Shaw S The link between substance abuse and posttraumatic stress disorder in women: a research review Am J Addict 1997 6 4 237 83 9398925
  28. [34]Brady KT Dansky BS Back SE Exposure therapy in the treatment of PSTD among cocaine-dependent individuals: preliminary findings J Subst Abuse Treat 2001 21 47 54 11516926
  29. [35]Back SE Dansky BS Carroll KM Exposure therapy in the treatment of PTSD among cocaine-dependent individuals: description of procedures J Subst Abuse Treat 2001 21 1 35 45 11516925
  30. [36]Hien DA Brady KT Back SE Greenfield SF Trauma, posttraumatic stress disorder and addiction among women Women and addiction: a comprehensive handbook 2009 242 56 Guilford Press New York
  31. [37]Najavits LM Seeking safety: a treatment manual for PTSD and substance abuse 2002 Guilford Press New York
  32. [38]Brady KT Sonne SC Roberts JM Sertraline treatment of comorbid posttraumatic stress disorder and alcohol dependence J Clin Psychiatry 1995 56 502 5 7592501
  33. [39]Brady KT Sonne S Anton RF Sertraline in the treatment of co-occurring alcohol dependence and posttraumatic stress disorder Alcohol Clin Exp Res 2005 29 3 395 401 15770115
  34. [40]Labbate LA Sonne SC Randal CL Does comorbid anxiety or depression affect clinical outcomes in patients with post-traumatic stress disorder and alcohol use disorders? Compr Psychiatry 2004 45 4 304 10 15224273
  35. [41]Keyes KM Grant BF Hasin DS Evidence for a closing gender gap in alcohol use, abuse, and dependence in the United States population Drug Alcohol Depend 2008 93 21 9 17980512 PMC3163892
  36. [42]Brady KT Randall CL Gender differences in substance use disorders Psychiatr Clin North Am 1999 22 241 52 10385931
  37. [43]Frezza M Pozzato G Chiesa L Abnormal serum gamma-glutamyltrans-peptidase in alcoholics. Clues to its explanation Neth J Med 1989 34 1–2 22 8 2563572
  38. [45]Stewart SH Gavric D Collins P Brady KT Back SE Greenfield SF Women, girls, and alcohol Women & addiction 2009 341 59 Guilford Press New York
  39. [47]Ashley OS Marsden ME Brady TM Effectiveness of substance abuse treatment programming for women: a review Am J Drug Alcohol Abuse 2003 29 19 53 12731680
  40. [48]Dahlgren L Willander A Are special treatment facilities for female alcoholics needed? A controlled 2-year follow-up study from a specialized female unit (EWA) versus a mixed male/female treatment facility Alcohol Clin Exp Res 1989 13 499 504 2679204
  41. [49]Greenfield SF Trucco EM McHugh RK The Women’s Recovery Group Study: a stage I trial of women-focused group therapy for substance use disorders versus mixed-gender group drug counseling Drug Alcohol Depend 2007 90 39 47 17446014 PMC3679366
  42. [51]Lynch WJ Sex differences in vulnerability to drug self-administration Exp Clin Psychopharmacol 2006 14 1 34 41 16503703
  43. [52]Westermeyer J Boedicker AE Course, severity, and treatment of substance abuse among women versus men Am J Drug Alcohol Abuse 2000 26 4 523 35 11097190
  44. [54]Della Grotta S LaGasse LL Arria AM Accessed January 28, 2010 Patterns of methamphetamine use during pregnancy: results from the Infant Development, Environment, and Lifestyle (IDEAL) Study Matern Child Health J 2009 Available at: http://www.springerlink.com/content/l70457522w85q525/fulltext.html PMC2895902 19565330
  45. [55]Terplan M Smith EJ Kozoloski MJ Methamphetamine use among pregnant women Obstet Gynecol 2009 113 1285 91 19461424
  46. [56]Sofuoglu M Mitchell E Kosten TR Effects of progesterone treatment on cocaine responses in male and female cocaine users Pharmacol Biochem Behav 2004 78 4 699 705 15301924
  47. [57]Hser YI Evans E Huang YC Treatment outcomes among women and men methamphetamine abusers in California J Subst Abuse Treat 2005 28 1 77 85 15723735
  48. [58]Rowan-Szal GA Joe GW Simpson DD During-treatment outcomes among female methamphetamine-using offenders in prison-based treatments J Offender Rehabil 2009 8 388 401 19710949 PMC2731425
  49. [59]Campbell UC Morgan AD Carroll ME Sex differences in the effects of baclofen on the acquisition of intravenous cocaine self-administration in rats Drug Alcohol Depend 2002 66 1 61 9 11850137
  50. [60]Pettinati HM Kampman KM Lynch KG Gender differences with high-dose naltrexone in patients with co-occurring cocaine and alcohol dependence J Subst Abuse Treat 2008 34 4 378 90 17664051 PMC2600888
  51. [63]Tetrault JM Desai RA Becker WC Gender and non-medical use of prescription opioids: results from a national US survey Addiction 2008 103 258 68 18042194
  52. [65]McCabe SE Cranford JA Boyd CJ Motives, diversion and routes of administration associated with nonmedical use of prescription opioids Addict Behav 2007 32 3 562 75 16843611 PMC1766373
  53. [66]Back SE Payne R Waldrop AE Prescription opioid aberrant behaviors: a pilot study of gender differences Clin J Pain 2009 25 477 84 19542794 PMC2771580
  54. [67]Powis B Griffiths P Gossop M The differences between male and female drug users: community samples of heroin and cocaine users compared Subst Use Misuse 1996 31 5 529 43 8777737
  55. [68]Kelly SM Schwartz RP O’Grady KE Gender differences among in- and out-of-treatment opioid-addicted individuals Am J Drug Alcohol Abuse 2009 35 1 38 42 19152205 PMC2938871
  56. [69]Bryant J Treload C The gendered context of initiation to injecting drug use: evidence for women as active initiates Drug Alcohol Rev 2007 26 287 93 17454018
  57. [70]Frajzyngier V Neaigus A Gyarmathy VA Gender differences in injection risk behaviors at the first injection episode Drug Alcohol Depend 2007 89 145 52 17276623
  58. [71]Breen C Roxburgh A Degenhardt L Gender differences among regular injecting drug users in Sydney, Australia, 1996–2003 Drug Alcohol Rev 2005 24 353 8 16234131
  59. [72]Montgomery SB Hyde J De Rosa CJ Gender differences in HIV risk behaviors among young injectors and their social network members Am J Drug Alcohol Abuse 2002 28 3 453 75 12211360
  60. [74]Najavits LM Rosier M Nolan AL A new gender-based model for women’s recovery from substance abuse: results of a pilot outcome study Am J Drug Alcohol Abuse 2007 33 1 5 11 17366241
  61. [75]Jones HE Fitzgerald H Johnson RE Males and females differ in response to opioid agonist medications Am J Addict 2005 14 223 33 16019973
  62. [78]Van Etten ML Anthony JC Comparative epidemiology of initial drug opportunities and transitions to first use: marijuana, cocaine, hallucinogens, and heroin Drug Alcohol Depend 1999 54 117 25 10217551
  63. [80]Griffin ML Mendelson JH Mello NK Marijuana use across the menstrual cycle Drug Alcohol Depend 1986 18 213 24 3780416
  64. [81]Lex BW Mendelson JH Bavli S Effects of acute marijuana smoking on pulse rate and mood states in women Psychopharmacology 1984 84 178 87 6438677
  65. [83]Pope HG Gruber AJ Hudson JI Neuropsychological performance in long-term cannabis users Arch Gen Psychiatry 2001 58 909 15 11576028
  66. [84]Pope HG Jacobs A Mialet JP Evidence for a sex-specific residual effect of cannabis on visuospatial memory Psychother Psychosom 1997 66 179 84 9259040
  67. [85]Budney AJ Higgins ST Radonovich PL Adding voucher-based incentives to coping skills and motivational enhancement improves outcomes during treatment for marijuana dependence J Consult Clin Psychol 2000 68 1051 61 11142539
  68. [86]Haney M Hart CL Ward AS Nefazodone decreases anxiety during marijuana withdrawal in humans Psychopharmacology 2003 165 157 65 12439626
  69. [87]Haney M Hart CL Vosburg SK Marijuana withdrawal in humans: effects of oral THC or divalproex Neuropsychopharmacology 2004 29 158 70 14560320
  70. [90]Dransfield MT Davis JJ Gerald LB Racial and gender differences in susceptibility to tobacco smoke among patients with chronic obstructive pulmonary disease Respir Med 2006 100 1110 6 16236491
  71. [91]International Early Lung Cancer Action Program Investigators Women’s susceptibility to tobacco carcinogens and survival after diagnosis of lung cancer JAMA 2006 296 180 4 16835423
  72. [93]Perkins KA Jacobs L Sanders M Sex differences in the subjective and reinforcing effects of cigarette nicotine dose Psychopharmacology 2002 163 194 201 12202966
  73. [94]Perkins KA Doyle T Ciccocioppo M Sex differences in the influence of nicotine and dose instructions on subjective and reinforcing effects of smoking Psychopharmacology 2006 184 600 7 16075290
  74. [95]Perkins KA Gerlach D Vender J Sex differences in the subjective and reinforcing effects of visual and olfactory cigarette smoke stimuli Nicotine Tob Res 2001 3 141 50 11403728
  75. [96]Centers for Disease Control and Prevention Cigarette smoking among adults—United States, 2005 MMWR Morb Mortal Wkly Rep 2006 55 1145 8 17065979
  76. [97]Rodu B Cole P Declining mortality from smoking in the United States Nicotine Tob Res 2007 9 781 4 17577808
  77. [98]Pirie PL Murray DM Luepker RV Gender differences in cigarette smoking and quitting in a cohort of young adults Am J Public Health 1991 81 324 7 1994740 PMC1405015
  78. [99]Swan GE Ward MM Carmelli D Differential rates of relapse in subgroups of male and female smokers J Clin Epidemiol 1993 46 1041 53 8263577
  79. [100]Munafo M Bradburn M Bowes L Are there sex differences in transdermal nicotine replacement therapy patch efficacy? A meta-analysis Nicotine Tob Res 2004 6 769 76 15700912
  80. [101]Perkins KA Scott J Sex differences in long-term smoking cessation rates due to nicotine patch Nicotine Tob Res 2008 10 1245 51 18629735
  81. [102]Gonzales D Rennard SI Nides M Varenicline, an a4b2 nicotinic acetylcholine receptor partial agonist, vs. sustained-release bupropion and placebo for smoking cessation J Am Med Assoc 2006 296 47 55 16820546
  82. [103]Scharf D Shiffman S Are there gender differences in smoking cessation, with and without bupropion? Pooled and meta-analyses of clinical trials of Bupropion SR Addiction 2004 99 1462 9 15500599
  83. [104]Cepeda-Benito A Reynoso JT Erath S Meta-analysis of the efficacy of nicotine replacement therapy for smoking cessation: differences between men and women J Consult Clin Psychol 2004 72 712 22 15301656
  84. [105]England LJ Grauman A Qian C Misclassification of maternal smoking status and effects on an epidemiologic study of pregnancy outcomes Nicotine Tob Res 2007 9 1005 13 17852766
  85. [106]McBride CM Pirie PL Postpartum smoking relapse Addict Behav 1990 15 165 8 2343790
  86. [109]Kelly PJ Blacksin B Mason E Factors affecting substance abuse treatment completion for women Issues Ment Health Nurs 2001 22 287 304 11885213
  87. [110]Loneck B Garrett J Banks SM Engaging and retaining women in outpatient alcohol and other drug treatment: the effect of referral intensity Health Soc Work 1997 22 38 46 9021417
  88. [111]Schmidt L Weisner C Galanter M The emergence of problem-drinking women as a special population in need of treatment Recent developments in alcoholism: alcoholism and women 1995 309 34 Plenum Press New York 7624551
  89. [113]Conners NA Bradley RH Mansell LW Children of mothers with serious substance abuse problems: an accumulation of risks Am J Drug Alcohol Abuse 2004 30 1 85 100 15083555
  90. [115]Lundgren LM Schilling RF Fitzgerald T Parental status of women injection drug users and entry to methadone maintenance Subst Use Misuse 2003 38 8 1109 31 12901451
  91. [116]Haller DL Miles DR Dawson KS Factors influencing treatment enrollment by pregnant substance abusers Am J Drug Alcohol Abuse 2003 29 1 117 31 12731684
  92. [118]Greenfield SF Grella CE Alcohol & drug abuse: what is “women-focused” treatment for substance use disorders? Psychiatr Serv 2009 60 880 2 26650590
  93. [120]Volpicelli J Markman I Monterosso J Psychosocially enhanced treatment for cocaine-dependent mothers: evidence of efficacy J Subst Abuse Treat 2000 18 41 9 10636605
  94. [121]Smith WB Weisner C Women and alcohol problems: a critical analysis of the literature and unanswered questions Alcohol Clin Exp Res 2001 24 1320 1 10968672
  95. [122]Condelli WS Koch MA Fletcher B Treatment refusal/attrition among adults randomly assigned to programs at a drug treatment campus. The New Jersey Substance Abuse Treatment Campus, Seacaucus, NJ J Subst Abuse Treat 2000 18 395 407 10812314
  96. [123]Strantz IH Welch SP Postpartum women in outpatient drug abuse treatment: correlates of retention/completion J Psychoactive Drugs 1995 27 357 73 8788692
  97. [124]Kaskutas LA Zhang L French MT Women’s programs versus mixedgender day treatment: results from a randomized study Addiction 2005 100 60 9 15598193
  98. [125]Greenfield SF Potter JS Lincoln MF High psychiatric severity is a moderator of substance abuse treatment outcomes among women in single vs. mixed gender group treatment Am J Drug Alcohol Abuse 2008 34 594 602 18821452 PMC2917826
  99. [126]Cummings A Gallop R Self-efficacy and substance use outcomes for women in single gender versus mixed-gender group treatment J Groups Addict Recover 2010 in press PMC3132800 21753920
  100. [127]Connors GJ Maisto SA Zywiak WH Male and female alcoholics’ attributions regarding the onset and termination of relapses and the maintenance of abstinence J Subst Abuse 1998 10 27 42 9720004
  101. [128]Fals-Stewart W Birchler GR Kelley ML Learning sobriety together: a randomized clinical trial examining behavioral couples therapy with alcoholic female patients J Consult Clin Psychol 2006 74 579 91 16822114

Cited by

Sorted by citations

Authors
Greenfield, S. F., Back, S. E., Lawson, K., & Brady, K. T.
Affiliations
  • Harvard University (US)
  • Medical University of South Carolina (US)
Corresponding author
Greenfield, Shelly F.
ORCID
Venue
Psychiatric Clinics of North America
Publisher
Elsevier BV
Published
2010-06
Volume
33
Issue
2
Pages
339-355
ISSN
0193-953X (ISSN-L)
DOI
10.1016/j.psc.2010.01.004
PMC
PMC3124962
OpenAlex
W2079022215
Cited by
602
References
13
Citations by year
2026: 39 · 2025: 31 · 2024: 30 · 2023: 34 · 2022: 42 · 2021: 50 · 2020: 60 · 2019: 45 · 2018: 40 · 2017: 52 · 2016: 40 · 2015: 45 · 2014: 30 · 2013: 18 · 2012: 25
FWCI
2.30
Type
journal article
Language
en
Open access
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Psychiatric Clinics of North America (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health (5k24da019855-10)
  • National Institute on Drug Abuse (K24DA00435, K24-DA019855, P50DA016511, K24DA000435, K23DA021228)
Topics
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Social Sciences › Psychology › Clinical Psychology › Gambling Behavior and Treatments
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
Keywords
gender differences, prevalence ratio, sex steroids, craving, relapse, stress reactivity, anxiety disorders, eating disorders, post-traumatic stress disorder, alcohol consumption, stimulants, opioids, cannabis, nicotine, substance abuse treatment outcomes, treatment retention, gender-specific treatment
MeSH terms
Adult, Anxiety, Feeding and Eating Disorders, Female, Humans, Male, Psychotherapy, Risk Factors, Sex Factors, Gonadal Steroid Hormones, Stress Disorders, Post-Traumatic, Stress, Psychological, Comorbidity, Treatment Outcome, Mood Disorders, Substance-Related Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review